长期治疗慢性乙型肝炎HBV DNA抑制导致肝硬化逆转

StephenW

下载完整文章:http://onlinelibrary.wiley.com/doi/10.1111/jgh.12213/pdf

Source: J Gastroenterol Hepatol  |  Posted 2 days ago
Long-term therapy for chronic hepatitis B: HBV DNA suppression leading to cirrhosis reversal;

Marcellin P, Asselah T; Journal of Gastroenterology and Hepatology (Apr 2013)


Since the licensing of the first treatment for chronic hepatitis B (CHB) in the nucleoside/tide analogue (NA) class almost 15 years ago, considerable progress has been made in improving drug efficacy and safety with highly potent NAs exhibiting a high barrier to resistance. Physicians are now able to treat patients safely for many years and to be able to see convincing improvements in histology, including regression of fibrosis and even reversal of cirrhosis. The robust data that have been generated help us build confidence that we can now offer patients with CHB long-term, disease-modifying therapy that can alter the natural course of disease and help prevent the morbidity and mortality associated with it.

StephenW

来源：胃肠肝脏病杂志|发表于3天前
长期治疗慢性乙型肝炎HBV DNA抑制导致肝硬化逆转;

Marcellin等Asselah P，T，胃肠病学和肝病学杂志（2013年4月）


在核苷/潮类似物（NA）类近15年前的第一次治疗慢性乙型肝炎（CHB）的发牌，已取得长足的进步，在提高药物的疗效和安全性与高度有效的NAS呈现高耐药屏障。医生们现在能够安全治疗多年，能够看到令人信服的组织学改善，包括回归纤维化甚至肝硬化的逆转。强大的数据已生成帮助我们建立信心，我们现在可以提供慢性乙肝长期疾病修饰治疗的患者，可以改变疾病的自然病程，并有助于防止与它相关的发病率和死亡率。